Skip to main content
Back
TWAPF logo

Towa Pharmaceutical Co., Ltd.

Data quality: 100%
Overbought
TWAPF
OTC Healthcare Drug Manufacturers - Specialty & Generic
$16.83
$0.00 (0.00%)
Mkt Cap: 828.51M
Day Range
$16.83 $25.33
52-Week Range
$16.83 $25.33
Volume
200
50D / 200D Avg
$16.83 / $16.83
Prev Close
$16.83

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 0.0 0.4
P/B 0.0 2.9
ROE % 11.6 3.8
Net Margin % 7.3 3.9
Rev Growth 5Y % 13.8 10.0
D/E 1.4 0.2

Key Takeaways

Revenue grew 13.78% annually over 5 years — strong growth
Earnings grew 17.39% over the past year
ROE of 11.59% — decent returns on equity
Negative free cash flow of -7.82B
P/E of 0.04 — trading at a low valuation
PEG of 0.54 suggests growth is underpriced

Growth

Revenue Growth (5Y)
13.78%
Revenue (1Y)13.89%
Earnings (1Y)17.39%
FCF Growth (3Y)N/A

Quality

Return on Equity
11.59%
ROIC4.33%
Net Margin7.31%
Op. Margin8.95%

Safety

Debt / Equity
1.35
Current Ratio2.81
Interest Coverage14.29

Valuation

P/E Ratio
0.04
P/B Ratio0.00
EV/EBITDA8.02
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13.89% Revenue Growth (3Y) 11.49%
Earnings Growth (1Y) 17.39% Earnings Growth (3Y) 193.70%
Revenue Growth (5Y) 13.78% Earnings Growth (5Y) 7.99%
Profitability
Revenue (TTM) 259.59B Net Income (TTM) 18.99B
ROE 11.59% ROA 4.03%
Gross Margin 36.49% Operating Margin 8.95%
Net Margin 7.31% Free Cash Flow (TTM) -7.82B
ROIC 4.33% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.35 Current Ratio 2.81
Interest Coverage 14.29 Dividend Yield 0.02%
Valuation
P/E Ratio 0.04 P/B Ratio 0.00
P/S Ratio 0.00 PEG Ratio 0.54
EV/EBITDA 8.02 Dividend Yield 0.02%
Market Cap 828.51M Enterprise Value 186.34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 259.59B 227.93B 208.86B 165.62B 154.90B
Net Income 18.99B 16.17B 2.20B 15.91B 13.96B
EPS (Diluted) 385.71 328.59 44.72 316.19 271.93
Gross Profit 94.73B 81.38B 72.71B 70.19B 65.45B
Operating Income 23.24B 17.65B 5.51B 19.21B 19.92B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 470.82B 430.65B 371.35B 329.94B 245.67B
Total Liabilities 299.20B 274.76B 234.45B 197.77B 129.07B
Shareholders' Equity 171.62B 155.89B 136.89B 132.17B 116.60B
Total Debt 230.98B 202.36B 173.07B 144.13B 84.77B
Cash & Equivalents 45.47B 29.65B 24.26B 32.83B 22.92B
Current Assets 247.31B 217.72B 182.99B 166.86B 137.29B
Current Liabilities 87.94B 80.12B 78.53B 115.07B 51.52B

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#540 of 616
12

Recent Activity

Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026